$1.84
2.13%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US03476J1079
Symbol
ELTX

Angion Biomedica Corp Stock price

$1.84
-1.17 38.87% 1M
-9.12 83.21% 6M
-6.12 76.88% YTD
-9.01 83.04% 1Y
-6.01 76.56% 3Y
-102.16 98.23% 5Y
-168.36 98.92% 10Y
-168.36 98.92% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.04 2.13%
ISIN
US03476J1079
Symbol
ELTX
Industry

Is Angion Biomedica Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$48.4m
Enterprise Value
$34.4m
Net debt
positive
Cash
$23.5m
Shares outstanding
21.9m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.1
Financial Health
Equity Ratio
6.3%
Return on Equity
-
ROCE
-171.3%
ROIC
-571.9%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-37.7m
EBIT
$-37.9m
Net Income
$-37.8m
Free Cash Flow
$-37.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
15.8%
EBIT
15.1%
Net Income
30.7%
Free Cash Flow
-7.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-2.0
FCF per Share
$-1.7
Short interest
8.2%
Employees
33
Rev per Employee
-

Angion Biomedica Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Angion Biomedica Corp forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Angion Biomedica Corp forecast:

Buy
80%
Hold
20%

Financial data from Angion Biomedica Corp

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
19% 19%
-
- Research and Development Expense 24 24
28% 28%
-
-38 -38
16% 16%
-
- Depreciation and Amortization 0.18 0.18
220% 220%
-
EBIT (Operating Income) EBIT -38 -38
15% 15%
-
Net Profit -38 -38
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Angion Biomedica Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Angion Biomedica Corp Stock News

Neutral
GlobeNewsWire
●
2 days ago
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company develo...
Neutral
GlobeNewsWire
●
about one month ago
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston...
Neutral
GlobeNewsWire
●
about one month ago
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026
More Angion Biomedica Corp News

Company Profile

Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Head office United States
CEO Mr. Connelly
Employees 33
Founded 2011
Website elicio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today